Preventing Packaging Errors from Disrupting a Multi-Country Clinical Trial
In complex clinical trials, packaging and labelling are often treated as necessary executional steps — but secondary. In reality, they are critical control points. Errors in packaging do not remain isolated. They can delay site activation, trigger rework, create regulatory exposure, and ultimately disrupt patient continuity. This case study explores how BAP Pharma supported a […]
Protecting Study Continuity Through Local Sourcing in China
The Challenge A leading BAP Pharma client required urgent local sourcing in China for a decentralised clinical study in immunology. The immediate need was to secure supply of Skyrizi® 360 mg and 600 mg within an accelerated one-month timeline, without disrupting patient treatment or wider study continuity.Operating in a complex local market under significant time […]
Accelerating Phase III Trial Restart in Turkey: End-to-end recovery delivered in under 7 days across 17 clinical sites
The Challenge A critical Phase III cardiovascular trial restart was placed at immediate risk when a previous supplier failed to deliver six essential standard-of-care (AxMP) medications across 17 clinical sites in Turkey. With no room for delay, the consequences were significant: missed dosing windows, inactive sites, and further disruption to study timelines and costs. The […]
Managing Multi-Country Labelling Complexity Without Delaying Trial Timelines
In multi-country clinical trials, labelling complexity increases rapidly. Different regulatory requirements, language variations, and country-specific interpretations all converge at a single point: the label. While often seen as an administrative step, labelling is in fact a compliance-critical component of trial delivery. Even minor inconsistencies can trigger delays, rework, or regulatory scrutiny.This case study explores how […]
Why are people with EDS and HSD receiving such late access to innovative therapies?
The Ehlers-Danlos Society – Why are people with EDS and HSD receiving such late access to innovative therapies? What is Ehlers-Danlos syndrome and hypermobility spectrum disorders? The Ehlers-Danlos syndromes are a group of heritable connective tissue disorders. Each type is caused by genetic variants that prevent connective tissue from functioning properly. Twelve types of EDS […]
BAP Pharma Report 2025
Ensuring ongoing access to sought-after medicinal products for patients is becoming increasingly important, but many regulatory, logistical, and financial hurdles must be overcome. There is also a growing need to provide access to unlicensed, pre-approved drugs.
In this whitepaper, we will explore how pharma and biotech companies can devise efficient medicines access strategies and, in doing so, maximise the potential of their products while not only enabling continued access for patients with an unmet medical need but also reaching new patients on a global level.
Travel Plan Infographic
Ensuring ongoing access to sought-after medicinal products for patients is becoming increasingly important, but many regulatory, logistical, and financial hurdles must be overcome. There is also a growing need to provide access to unlicensed, pre-approved drugs.
In this whitepaper, we will explore how pharma and biotech companies can devise efficient medicines access strategies and, in doing so, maximise the potential of their products while not only enabling continued access for patients with an unmet medical need but also reaching new patients on a global level.
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
LEXINGTON, Mass. And MARLOW, UK – [April 21, 2026] – Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus’ global partner for their botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. The […]
Buckinghamshire Council Travel Plan
Ensuring ongoing access to sought-after medicinal products for patients is becoming increasingly important, but many regulatory, logistical, and financial hurdles must be overcome. There is also a growing need to provide access to unlicensed, pre-approved drugs.
In this whitepaper, we will explore how pharma and biotech companies can devise efficient medicines access strategies and, in doing so, maximise the potential of their products while not only enabling continued access for patients with an unmet medical need but also reaching new patients on a global level.